Dapagliflozin in Patients with Chronic Kidney Disease
2020 · New England Journal of Medicine · 4,895 citations
https://doi.org/10.1056/nejmoa2024816
B
Bergur V. Stefánsson
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
83
Papers
9.6K
Citations
33
h-index
49
i10-index
Bergur V. Stefánsson is an academic researcher from Gentofte Hospital. The author has contributed to research in topics: Diabetes Treatment and Management & Chronic Kidney Disease and Diabetes & Pancreatic function and diabetes. The author has an h-index of 33, co-authored 71 publications.
ORCID: 0000-0002-0777-5373Papers by this author
worksA pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
2021 · Kidney International · 369 citations
https://doi.org/10.1016/j.kint.2021.03.033
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus
2018 · BMC Nephrology · 115 citations
https://doi.org/10.1186/s12882-018-0942-1
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
2016 · Diabetologia · 94 citations
https://doi.org/10.1007/s00125-016-4017-1
A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients
2015 · BMC Nephrology · 61 citations
https://doi.org/10.1186/s12882-015-0110-9
Angiotensin-Converting Enzyme Gene I/D Polymorphism in Malignant Hypertension
2000 · Blood Pressure · 25 citations
https://doi.org/10.1080/080370500453429
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat